NEW YORK (Reuters Health) – Single-agent subcutaneous epcoritamab appears to benefit patients with relapsed or refractory B-cell non-Hodgkin lymphoma, results of an ongoing early trial suggest. Epcoritamab is “a novel bispecific antibody that targets CD3 and CD20 and induces T-cell-mediated cytotoxic activity against CD20+ malignant B cells,” the study team explains in The Lancet. “Epcoritamab […]